MAR 01, 2017 10:30 AM PST

New Molecule Halts Growth of Fatal Pediatric Brain Tumor

WRITTEN BY: Xuan Pham

A sinister brain tumor that claims the lives of every affected child may now be stopped with a new molecule drug.

The brain tumor is known as diffuse intrinsic pontine glioma (DIPG), and it affects about 300 children every year in the US. The tumor is located in the pons of the brain, a part of the brainstem that relays messages from the forebrain to the cerebellum. “This tumor kills every single kid who gets DIPG within one year. No one survives,” said Andrea Piunti, underscoring the extremely aggressive nature of this tumor. Piunti is the study’s first author who is a postdoctoral fellow at the Northwestern University Feinberg School of Medicine.

Previously, the same lab identified a potential pathway mutation behind DIPG. In particular, they published that a mutation in the histone H3 molecule may be driving the growth of DIPG in fruit fly models. In follow-up work, the team demonstrated that a drug that corrected the effects of the mutation was able to prolong survival in mice by 20 days.

Now, the team sought to demonstrate the effects of the drug in DIPG patient-derived tumors in mice when directly injected in the brainstem. The drug is a BET bromodomain inhibitor, which prevent binding of bromodomain proteins to the mutant histone protein. These molecules are already used in a variety of other clinical trials as potential cancer therapies.

The team observed that treatment with the drug halted the tumor growth in mice. Furthermore, the drug triggered differentiation in the tumor cells, which also contributed to the reduction in tumor growth. Mice treated with BET inhibitor had significantly extended survival as compared to untreated mice.

“To the best of our knowledge, this is the most effective molecule so far in treating this tumor,” said Dr. Ali Shilatifard, the study’s senior author. “Every other therapy that has been tried so far has failed.”

Because BET inhibitors are available and have been used to treat leukemia, the researchers hope to apply it to clinical trials for DIPG patients next. Additionally, the team postulated that the BET inhibitor may be combined with other promising DIPG therapies, such as histone deacetylase (HDAC) inhibitors, with positive synergistic effects.

Additional sources: Northwestern University

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 16, 2019
Cancer
OCT 16, 2019
This Ovarian Cancer Drug Prolongs Life
Niraparib is a drug and a PARP inhibitor that targets cancer cells without harming others. PARP inhibitors keep PARP -- proteins that fix damaged DNA in ca...
OCT 16, 2019
Cancer
OCT 16, 2019
Understanding aging: new research
We all do it every day, but there’s still so much we don’t understand about it. I’m talking about aging. But now new research published r...
OCT 16, 2019
Cancer
OCT 16, 2019
New research targets pancreatic cancer tumors' environment
New research published in the journal Nature Communications highlights the inner workings of how pancreatic cancer cells spread. Pancreatic cancer is one o...
OCT 16, 2019
Cancer
OCT 16, 2019
Not the fried food!
Stop! Put down those fries! Although we know that fried foods aren’t good for our health (though they sure do taste good!), new research from UMass A...
OCT 16, 2019
Drug Discovery & Development
OCT 16, 2019
Promising Drug for Prostate Cancer
Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Spec...
OCT 16, 2019
Cancer
OCT 16, 2019
Gut fungi linked to pancreatic cancer
In a recent paper published in Nature paper, researchers from the New York University (NYU) School of Medicine in NYC report that gut fungi may be lin...
Loading Comments...